Royalty Pharma Acquires $885 Million Royalty Interest in Amgen's Imdelltra for Small Cell Lung Cancer
核心洞察
Royalty Pharma acquired an $885 million royalty interest in Amgen's Imdelltra, a first-in-class bispecific T-cell engager approved for small cell lung cancer treatment.
Imdelltra targets DLL3 (搜索) protein overexpressed in SCLC and generated $215 million in first-half 2025 sales, with analyst projections reaching $2.8 billion by 2035.
The acquisition provides Royalty Pharma with a 7% royalty on worldwide net sales through 2038-2041, positioning the company to benefit from ongoing Phase 3 trials.
Royalty Pharma (NASDAQ: RPRX) has completed an $885 million acquisition of a royalty interest in Amgen's Imdelltra, a first-in-class bispecific T-cell engager (BiTE) approved for small cell lung cancer (SCLC) treatment. The deal, which could scale to $950 million with additional payments, represents a strategic investment in one of oncology's most challenging therapeutic areas.
Targeting an Underserved Cancer Population
Imdelltra, approved in May 2024, addresses a critical unmet medical need in SCLC, a disease with a five-year survival rate of just 7% for invasive cases. The drug operates through a novel mechanism, binding to DLL3 (搜索), a protein overexpressed in SCLC tumors, while simultaneously engaging CD3 (搜索) on T cells to activate the immune system against cancer cells.
The therapeutic's commercial performance has shown strong early momentum, generating $215 million in first-half 2025 sales. Industry analysts project Imdelltra could reach $2.8 billion in annual sales by 2035, reflecting the significant market opportunity in this underserved patient population.
Strategic Financial Structure
Under the acquisition terms, Royalty Pharma will receive a 7% royalty on Imdelltra's worldwide net sales, excluding China, with the royalty stream extending through 2038-2041. The company's investment positions it to benefit from Amgen's ongoing clinical development program, including Phase 3 trials DeLLphi-303 and DeLLphi-304, which could expand Imdelltra's label to first-line therapy.
The deal structure includes potential additional payments of $65 million if BeOne Medicines (搜索) exercises its option, demonstrating Royalty Pharma's ability to create upside opportunities within its acquisitions.
Proven Oncology Portfolio Strategy
This acquisition reinforces Royalty Pharma's established oncology investment approach, joining a portfolio that includes stakes in blockbuster cancer drugs Xtandi (Pfizer/Astellas) and Imbruvica (AbbVie (搜索)/J&J), which each generated $46 million in royalty receipts in 2024. Xtandi's royalties demonstrated particular strength with 20% year-over-year growth in Q4 2024.
Recent additions to the company's oncology portfolio include a $350 million synthetic royalty on Niktimvo for graft-versus-host disease and a $125 million stake in Rytelo for myelodysplastic syndromes, illustrating the company's focus on niche but high-impact therapeutic areas.
Market Performance and Financial Position
The Imdelltra acquisition contributed to investor confidence, with Royalty Pharma's share price increasing 11% over the last quarter. Over the past year, the company delivered a total return of 31.42%, significantly outperforming the broader US Pharmaceuticals industry, which posted a negative 12.9% return over the same period.
Despite recent gains, shares trading at $36.32 remain below the analyst consensus price target of $43.27, suggesting potential upside. The company maintains strong financial flexibility with $929 million in cash and a $3.0 billion share repurchase program announced in January 2025.
Long-term Growth Trajectory
Analysts forecast Royalty Pharma's revenue could reach approximately $4 billion by August 2028, driven by strategic acquisitions like Imdelltra and the company's diversified revenue streams from established therapies. The acquisition aligns with the company's strategy of identifying therapies at critical inflection points that address specific unmet medical needs.
The investment in Imdelltra represents more than a financial transaction—it positions Royalty Pharma to participate in a potential paradigm shift in SCLC treatment, where effective therapeutic options have historically been limited.